Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.

Tri Juli Edi TariganAdisti DwijayantiSusie SetyowatiMelva Louisa

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2021)

Overall, insulin glargine biosimilar EZL and originator insulin glargine LAN have shown a similar immunogenicity profile, as well as efficacy in providing glucose control and safety findings in T2D populations.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
metabolic syndrome